Recent Publications and Grants

Engaged in diverse basic, translational and clinical research, our faculty routinely publish in prestigious journals and successfully compete for major grants from national funders.

Recent Publications

Research Grants

  • A phase 3 double-blind study to evaluate the efficacy and safety of oral ozanimod compared to oral fingolimod in children and adolescents with relapsing-remitting multiple sclerosis. Michael Dwyer, III (Co-Investigator). Bristol Myers Squibb. $1,649,376. 6/1/2023-12/1/2032.
  • Clinical and Translational Sciences Institute. Ram Samudrala (Co-Investigator). National Center for Advancing Translational Sciences. $29,204,726. 1/1/2026-12/1/2032.
  • CTSA State University of New York at Buffalo. Zackary Falls (Contributor). National Center for Advancing Translational Sciences (NCATS). $29,204,726. 1/1/2025-12/1/2031.
  • Clinical and Translational Science Award. Core Operations Special Populations. Ralph Benedict (Co-Investigator). NIH. $29,204,726. 1/1/2025-12/1/2031.
  • CTSA UM1 State University of New York at Buffalo. Bonnie Vest (Other). NIH. 1/1/2025-12/1/2031.
  • The impact of tissue microenvironment on monocyte permissiveness to arthritogenic alphavirus infections. Autumn Holmes (Principal Investigator). Howard Hughes Medical Institute. $1,680,000. 11/1/2026-11/1/2031.
  • Empowering Older Adults with Type 2 Diabetes Using Continuous Glucose Monitoring and Health Coaching for Individualized, Values-Concordant Care. Jennifer Campbell (Co-Investigator). NIH NIDDK. 9/1/2026-9/1/2031.
  • Efficacy of Continuous Glucose Monitoring Relative to Traditional Self-Monitoring of Blood Glucose in Non-Insulin Treated Adults with Poorly Controlled T2DM. Jennifer Campbell (Co-Investigator). NIH NIDDK. 8/1/2026-9/1/2031.
  • Conditional Cash Transfer and Basic Needs Resolution Intervention for Low Income Adults with T2DM. Jennifer Campbell (Principal Investigator). NIH NIDDK. 9/1/2026-9/1/2031.
  • Using the structures of natural product biosynthetic enzymes to guide the discovery of novel molecules (R35GM163992). Andrew Gulick (Principal Investigator). National Institutes of Health/NIGMS. 9/1/2026-8/1/2031.
  • N1T-MC-MALO:A Master Protocol for a RC, CT of Multiple Pharmacologic Agents in Adults w/Metabolic Dysfunction-Assoc. Steatotic Liver Disease who are at Increased Risk of Major Adverse Liver Outcomes (SYNERGY-Outcomes). Husam Ghanim (Contributor). Lilly Inc. $264,000. 8/1/2026-8/1/2031.
  • CTSA UM1 State University of New York at Buffalo. Praveen Chandrasekharan (Co-Investigator). NIH/NCATS. $29,204,726. 8/1/2025-7/1/2031.
  • Nef-independent SERINC5 regulation. Spyridon Stavrou (Principal Investigator). NIH/NIAID. $3,576,554. 7/1/2026-6/1/2031.
  • Efficacy of Continuous Glucose Monitoring Relative to Traditional Self-Monitoring of Blood Glucose in Non-Insulin Treated Adults with Poorly Controlled T2DM. Obinna Ekwunife (Co-Investigator). NIH/NIDDK. $3,998,816. 7/1/2026-6/1/2031.
  • Empowering older adults with type 2 diabetes using continuous glucose monitoring and health coaching for individualized, values-concordant care. Raphael Fraser (Principal Investigator). NIH/NIDDK. $3,749,950. 8/1/2026-6/1/2031.